DDInter1881 DDInter624
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saquinavir
Saquinavir {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nelfinavir
Nelfinavir {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Nevirapine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2B6 Inducers
Cytochrome P450 2B6 Inducers {u} (Pharmacologic Class) includes {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Simvastatin {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine (Compound) is included by Cytochrome P450 2B6 Inducers (Pharmacologic Class) and Cytochrome P450 2B6 Inducers (Pharmacologic Class) includes Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)